AnaBios offers early human insights into the drug development process and is redefining ‘First-in-Human’ studies. Leveraging extensive knowledge of human tissue procurement and strategic utilization

Peter Crowley​

Executive Chairman Peter Crowley joined MTS Health Partners, which makes equity investments in companies within the services sectors of the health care industry, in 20211 as an Operating Partner.

Learn More

Andre Ghetti

Chief Executive Officer Andre Ghetti, Ph.D., is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization.

Learn More

Jack A. Reynolds

Co-Founder And Chairman Emeritus Jack A. Reynolds, DVM, DACLAM, DACVP and FIATP is a Founding Partner and the Executive Chairman of AnaBios. He recently retired from Pfizer as Senior Vice President of R&D and Worldwide Head of Safety Sciences.

Learn More

David Anderson

Board Member David is a General Partner with Ampersand Capital. Prior to joining Ampersand in 2010, David spent six years with Covington Associates, a specialty investment bank focused on middle-market M&A in the healthcare sector.

Learn More

Melanie Fan

Board Member Melanie Fan is a Principal with Ampersand Capital Partners, having joined in 2018. Previously, she worked at Frazier Healthcare and UBS Investment Bank focusing on deals with middle market healthcare companies.

Learn More

Ric Erdman​

Board Member Ric Erdman started his business career in 1973 as a consultant with Arthur Andersen in New York City. He has raised more than $20 million in venture capital for companies he has founded and operated.

Learn More